

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: September 14, 2010

Electronic Signature for Nicholas J. DiCeglie, Jr.: /Nicholas J. DiCeglie, Jr./

Docket No.: [(5052D1) 69713DIV(304795)]
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jacques P. Dumas et al.

Application No.: 10/720,702

Confirmation No.: 5379

Filed: November 24, 2003

Art Unit: 1621

For: SUBSTITUTED PYRIDINES AND
PYRIDAZINES WITH ANGIOGENESIS
INHIBITING ACTIVITY

Examiner: P. G. O'Sullivan

INFORMATION DISCLOSURE STATEMENT (IDS)

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

In accordance with 37 CFR 1.98(d)(1), Applicant has not submitted copies of all other references, as all were previously cited by or provided to the Examiner in the parent application, U.S. Serial No. 09/672,294, now U.S. Patent No. 6,689,883.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 69713DIV(304795).

Dated: September 14, 2010

Respectfully submitted,

Electronic signature: Nicholas J. DiCeglie, Jr./
Nicholas J. DiCeglie, Jr.

Registration No.: 51,615
Edwards Angell Palmer & Dodge LLP
P.O. Box 55874
Boston, Massachusetts 02205
(212) 308-4411
Attorneys/Agents For Applicant

Customer No. 35969